Published: Tue, September 15, 2020

China coronavirus vaccine may be ready for general public by November

China coronavirus vaccine may be ready for general public by November

Adar Poonawalla said in an interview with the Financial Times that Vaccines for coronavirus treatment will take nearly four to five years until everybody to be vaccinated on this planet.

Dr. Anthony Fauci, the top infectious disease expert on the USA government's coronavirus task force, agreed on Wednesday that the temporary halting of the Phase-3 Oxford vaccine trial was "not uncommon". "I still don't see a proper plan on paper to do that [in India] beyond 400 million don't want a situation with the vaccine where you have capacity for your country but you can't consume it", he told the paper. In addition to this, SII can also cooperate with the Gamaleya Research Institute in Russian Federation to manufacture the Sputnik vaccine for COVID-19 treatment.

As part of its agreement with AstraZeneca, the company will aim to produce vaccine doses that cost around $3 for 68 countries and under its agreement with Novavax, for 92 countries.

On 8 September, nine drug companies, including Pfizer, released a joint statement to calm public fears over a vaccine being approved before being adequately tested.

Although initial studies didn't reveal serious side effects from the vaccine, rare complications of any vaccine, if there are any, may not turn up until it has been administered to thousands, or tens or thousands of people.

Despite the intense attention on the development of this particular COVID-19 vaccine, it is important to note these kinds of clinical trial pauses are routine.

In order to alleviate people's anxieties about vaccine safety, he said: If people have a trust deficit, I will be the first person to offer myself to receive the coronavirus vaccine.

There will not be enough doses of a COVID-19 vaccine to reach everyone worldwide until at least 2024, according to the CEO of the world's largest vaccine producer.

Hassan Valley, an epidemiologist from La Trobe University, suggests rather than this transitory pause being a cause for concern it should instead offer reassurance that this vaccine trial is being conducted using optimal safety precautions.

Serum Institute has a production and distribution alliance on this vaccine candidate in low- and middle-income countries.

Drug maker AstraZeneca announced Saturday that its COVID-19 vaccine studies have resumed in the United Kingdom, though not yet in the United States. A prolonged delay in the U.S. trial could slow access to the vaccine in the US.

Like this: